You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Investigational Drug Information for Reparixin


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 14 clinical trials for Reparixin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and Novartis.

There are fifty-one US patents protecting this investigational drug and seven hundred and twenty-one international patents.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)NovartisPhase 2
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Icahn School of Medicine at Mount SinaiPhase 2
Add-on Reparixin in Adult Patients With ARDSDompé Farmaceutici S.p.APhase 2

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

US Patents for Reparixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Reparixin ⤷  Try a Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try a Trial
Reparixin ⤷  Try a Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try a Trial
Reparixin ⤷  Try a Trial Combination therapy DIMERIX BIOSCIENCE PTY LTD. (Victoria, AU) ⤷  Try a Trial
Reparixin ⤷  Try a Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try a Trial
Reparixin ⤷  Try a Trial Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Reparixin

Drugname Country Document Number Estimated Expiration Related US Patent
Reparixin Canada CA2961033 2034-09-11 ⤷  Try a Trial
Reparixin European Patent Office EP3192791 2034-09-11 ⤷  Try a Trial
Reparixin Japan JPWO2016039408 2034-09-11 ⤷  Try a Trial
Reparixin World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11 ⤷  Try a Trial
Reparixin Argentina AR098909 2033-07-03 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.